AbbVie (NYSE: ABBV) EVP awarded performance stock and 19,500-share option
Rhea-AI Filing Summary
AbbVie Inc. executive Perry C. Siatis, EVP, GC and Secretary, reported multiple equity awards in AbbVie common stock. On February 18, 2026, he acquired several performance-based share awards, including 5,792, 5,628, 5,808 and 16,290 shares, all at a stated price of $0.00 per share.
Footnotes explain these represent performance-vesting awards and restricted stock units granted in 2023, 2024 and 2025, tied to earnings per share, relative total shareholder return and relative return on equity. The performance conditions were certified as achieved, and the related shares are scheduled to be issued on February 28, 2026. He also received an employee stock option covering 19,500 shares, vesting in three equal annual installments starting in 2027.
Positive
- None.
Negative
- None.
Insights
Routine performance-based equity vesting and option grant for AbbVie EVP.
The transactions show Perry C. Siatis receiving performance-based stock and restricted stock unit awards, plus a 19,500-share option, all classified as acquisitions rather than open-market purchases. The awards vest based on earnings per share, relative total shareholder return and return on equity metrics already certified by the compensation committee.
The option vests in three 6,500-share installments in 2027, 2028 and 2029 under AbbVie’s incentive plan. These equity grants are standard senior executive compensation mechanisms and do not, by themselves, signal a change in AbbVie’s financial outlook or strategy.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (Right to buy) | 19,500 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 16,290 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 5,792 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 5,628 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 5,808 | $0.00 | -- |
Footnotes (1)
- Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,500 on February 18, 2027, 6,500 on February 18, 2028, and 6,500 on February 18, 2029.
